Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
